HK1256903A1 - 治療人免疫缺陷病毒的治療組合物 - Google Patents
治療人免疫缺陷病毒的治療組合物Info
- Publication number
- HK1256903A1 HK1256903A1 HK18116014.8A HK18116014A HK1256903A1 HK 1256903 A1 HK1256903 A1 HK 1256903A1 HK 18116014 A HK18116014 A HK 18116014A HK 1256903 A1 HK1256903 A1 HK 1256903A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- treatment
- immunodeficiency virus
- human immunodeficiency
- therapeutic compositions
- therapeutic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562253042P | 2015-11-09 | 2015-11-09 | |
US201662399999P | 2016-09-26 | 2016-09-26 | |
PCT/US2016/060989 WO2017083304A1 (en) | 2015-11-09 | 2016-11-08 | Therapeutic compositions for treatment of human immunodeficiency virus |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1256903A1 true HK1256903A1 (zh) | 2019-10-04 |
Family
ID=57346085
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18115158.6A HK1256093A1 (zh) | 2015-11-09 | 2018-11-27 | 治療人免疫缺陷病毒的治療組合物 |
HK18116014.8A HK1256903A1 (zh) | 2015-11-09 | 2018-12-13 | 治療人免疫缺陷病毒的治療組合物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18115158.6A HK1256093A1 (zh) | 2015-11-09 | 2018-11-27 | 治療人免疫缺陷病毒的治療組合物 |
Country Status (28)
Country | Link |
---|---|
US (3) | US10548846B2 (zh) |
EP (2) | EP3632415A1 (zh) |
JP (1) | JP6621933B2 (zh) |
KR (4) | KR20230015512A (zh) |
CN (2) | CN108348473B (zh) |
AU (2) | AU2016354007C9 (zh) |
BR (1) | BR102016026127A2 (zh) |
CA (1) | CA2948021C (zh) |
CL (1) | CL2018001199A1 (zh) |
CO (1) | CO2018004776A2 (zh) |
CR (1) | CR20180253A (zh) |
EA (1) | EA201890654A1 (zh) |
EC (1) | ECSP18033723A (zh) |
ES (1) | ES2757560T3 (zh) |
HK (2) | HK1256093A1 (zh) |
IL (1) | IL258459A (zh) |
MX (1) | MX2018005729A (zh) |
NZ (1) | NZ741957A (zh) |
PE (1) | PE20181207A1 (zh) |
PH (1) | PH12018501001A1 (zh) |
PL (1) | PL3346995T3 (zh) |
PT (1) | PT3346995T (zh) |
SG (1) | SG11201802983TA (zh) |
SI (1) | SI3346995T1 (zh) |
SV (1) | SV2018005682A (zh) |
TW (2) | TWI737647B (zh) |
UY (1) | UY36981A (zh) |
WO (1) | WO2017083304A1 (zh) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY35213A (es) | 2012-12-21 | 2014-06-30 | Gilead Sciences Inc | Compuestos del tipo de las carbamilpiridonas policíclicas y su uso farmaceutico |
NO2717902T3 (zh) | 2014-06-20 | 2018-06-23 | ||
TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
RS62434B1 (sr) | 2014-12-26 | 2021-11-30 | Univ Emory | Antivirusni n4-hidroksicitidin derivati |
JP6621933B2 (ja) | 2015-11-09 | 2019-12-18 | ギリアード サイエンシス インコーポレーテッド | ヒト免疫不全ウイルスを処置するための治療組成物 |
JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
JP2020530024A (ja) * | 2017-08-09 | 2020-10-15 | ヴィーブ ヘルスケア カンパニー | 組み合わせ並びにその使用及び治療 |
US20200246351A1 (en) * | 2017-08-09 | 2020-08-06 | Viiv Healthcare Company | Combinations and uses and treatments thereof |
KR102626210B1 (ko) | 2017-12-07 | 2024-01-18 | 에모리 유니버시티 | N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도 |
PL3759109T3 (pl) | 2018-02-26 | 2024-03-04 | Gilead Sciences, Inc. | Podstawione związki pirolizyny jako inhibitory replikacji hbv |
CN112996517A (zh) * | 2018-09-19 | 2021-06-18 | 吉利德科学公司 | 预防hiv的整合酶抑制剂 |
CN111096954B (zh) * | 2018-10-29 | 2022-09-16 | 江苏豪森药业集团有限公司 | 一种用于抗病毒感染的药物组合物及制备方法 |
EP3653629A1 (en) * | 2018-11-16 | 2020-05-20 | Sandoz AG | Acid addition salts of an integrase strand transfer inhibitor |
CN111686082A (zh) * | 2019-03-11 | 2020-09-22 | 苏州特瑞药业有限公司 | 一种富马酸磷丙替诺福韦制剂及其制备方法 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1331208A (zh) | 2000-06-30 | 2002-01-16 | 上海博德基因开发有限公司 | 一种新的多肽——人肿瘤坏死因子受体21.45和编码这种多肽的多核苷酸 |
CN1291994C (zh) | 2000-07-21 | 2006-12-27 | 吉里德科学公司 | 核苷酸膦酸酯类似物前药及其筛选和制备方法 |
MY169670A (en) | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
EP1549315A4 (en) | 2002-09-11 | 2007-05-23 | Merck & Co Inc | DIHYDROXYPYRIDOPYRAZINE-1,6-DION COMPOUNDS AS HIV INTEGRASE INHIBITORS |
KR20090053867A (ko) | 2003-01-14 | 2009-05-27 | 길리애드 사이언시즈, 인코포레이티드 | 복합 항바이러스 치료를 위한 조성물 및 방법 |
EP1790638B1 (en) | 2004-09-15 | 2013-04-03 | Shionogi Co., Ltd. | Carbamoylpyridone derivative having hiv integrase inhibitory activity |
EP2465580B1 (en) | 2005-04-28 | 2013-12-18 | VIIV Healthcare Company | Polycyclic carbamoylpyridone derivatives having hiv integrase inhibitory activity |
TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
SG170795A1 (en) | 2005-12-30 | 2011-05-30 | Gilead Sciences Inc | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
WO2008043829A2 (en) | 2006-10-14 | 2008-04-17 | Boehringer Ingelheim International Gmbh | Method for treating hiv-1 infection by the combined administration of nevirapine, tenofovir and emtricitabine |
AU2010210598B2 (en) | 2009-02-06 | 2015-03-05 | Gilead Sciences, Inc. | Tablets for combination therapy |
CN106511357A (zh) * | 2010-11-19 | 2017-03-22 | 吉利德科学公司 | 包含利匹韦林HCl和富马酸替诺福韦酯的治疗组合物 |
ES2651212T3 (es) | 2011-07-07 | 2018-01-25 | Janssen Sciences Ireland Uc | Formulaciones combinadas de darunavir |
UY34262A (es) | 2011-08-16 | 2013-04-05 | Gilead Sciences Inc | Hemifumarato de tenofovir alafenamida, sus composiciones, método de preparación, métodos para tratar infecciones virales y su uso para preparar medi camentos |
AU2012327170A1 (en) | 2012-02-03 | 2013-08-22 | Gilead Sciences, Inc. | Therapeutic compounds |
CN104105484A (zh) * | 2012-02-03 | 2014-10-15 | 吉联亚科学公司 | 用于治疗病毒感染的包含替诺福韦艾拉酚胺半反丁烯二酸盐和可比西他的组合疗法 |
US20140221355A1 (en) | 2012-12-21 | 2014-08-07 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
UY35213A (es) | 2012-12-21 | 2014-06-30 | Gilead Sciences Inc | Compuestos del tipo de las carbamilpiridonas policíclicas y su uso farmaceutico |
NO2865735T3 (zh) * | 2013-07-12 | 2018-07-21 | ||
WO2015022351A1 (en) * | 2013-08-14 | 2015-02-19 | Ratiopharm Gmbh | Medicament comprising a pharmaceutical combination of dolutegravir, emtricitabine and tenofovir |
WO2015039348A1 (en) | 2013-09-23 | 2015-03-26 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors |
NO2717902T3 (zh) | 2014-06-20 | 2018-06-23 | ||
TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
TWI677489B (zh) | 2014-06-20 | 2019-11-21 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
CA2921336A1 (en) | 2015-06-30 | 2016-12-30 | Gilead Sciences, Inc. | Pharmaceutical formulations |
PT4070788T (pt) | 2015-06-30 | 2023-06-06 | Gilead Sciences Inc | Formulações farmacêuticas |
JP6621933B2 (ja) | 2015-11-09 | 2019-12-18 | ギリアード サイエンシス インコーポレーテッド | ヒト免疫不全ウイルスを処置するための治療組成物 |
KR102100436B1 (ko) | 2018-10-30 | 2020-04-13 | 울산과학기술원 | 강자성 원소 치환형 상온 다강성 물질 및 그 제조 방법 |
-
2016
- 2016-11-08 JP JP2018543287A patent/JP6621933B2/ja active Active
- 2016-11-08 CA CA2948021A patent/CA2948021C/en active Active
- 2016-11-08 US US15/346,335 patent/US10548846B2/en active Active
- 2016-11-08 TW TW105136333A patent/TWI737647B/zh active
- 2016-11-08 EP EP19186760.5A patent/EP3632415A1/en active Pending
- 2016-11-08 PL PL16798063T patent/PL3346995T3/pl unknown
- 2016-11-08 AU AU2016354007A patent/AU2016354007C9/en active Active
- 2016-11-08 MX MX2018005729A patent/MX2018005729A/es unknown
- 2016-11-08 BR BR102016026127A patent/BR102016026127A2/pt not_active Application Discontinuation
- 2016-11-08 TW TW110129951A patent/TW202220660A/zh unknown
- 2016-11-08 KR KR1020237001933A patent/KR20230015512A/ko not_active IP Right Cessation
- 2016-11-08 KR KR1020187015929A patent/KR102153996B1/ko active IP Right Grant
- 2016-11-08 PE PE2018000720A patent/PE20181207A1/es unknown
- 2016-11-08 NZ NZ741957A patent/NZ741957A/en unknown
- 2016-11-08 ES ES16798063T patent/ES2757560T3/es active Active
- 2016-11-08 PT PT167980630T patent/PT3346995T/pt unknown
- 2016-11-08 KR KR1020247017929A patent/KR20240095320A/ko unknown
- 2016-11-08 EA EA201890654A patent/EA201890654A1/ru unknown
- 2016-11-08 SI SI201630440T patent/SI3346995T1/sl unknown
- 2016-11-08 WO PCT/US2016/060989 patent/WO2017083304A1/en active Application Filing
- 2016-11-08 EP EP16798063.0A patent/EP3346995B1/en active Active
- 2016-11-08 SG SG11201802983TA patent/SG11201802983TA/en unknown
- 2016-11-08 CN CN201680065167.3A patent/CN108348473B/zh active Active
- 2016-11-08 CR CR20180253A patent/CR20180253A/es unknown
- 2016-11-08 CN CN202110669391.6A patent/CN113546052A/zh active Pending
- 2016-11-08 KR KR1020207025458A patent/KR102606625B1/ko active IP Right Grant
- 2016-11-09 UY UY0001036981A patent/UY36981A/es not_active Application Discontinuation
-
2018
- 2018-03-29 IL IL258459A patent/IL258459A/en unknown
- 2018-05-02 EC ECIEPI201833723A patent/ECSP18033723A/es unknown
- 2018-05-03 CL CL2018001199A patent/CL2018001199A1/es unknown
- 2018-05-03 SV SV2018005682A patent/SV2018005682A/es unknown
- 2018-05-03 CO CONC2018/0004776A patent/CO2018004776A2/es unknown
- 2018-05-08 PH PH12018501001A patent/PH12018501001A1/en unknown
- 2018-11-27 HK HK18115158.6A patent/HK1256093A1/zh unknown
- 2018-12-13 HK HK18116014.8A patent/HK1256903A1/zh unknown
-
2020
- 2020-02-12 AU AU2020200995A patent/AU2020200995B9/en active Active
- 2020-08-06 US US16/987,081 patent/US20210052502A1/en not_active Abandoned
-
2022
- 2022-05-06 US US17/738,803 patent/US11744802B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1256903A1 (zh) | 治療人免疫缺陷病毒的治療組合物 | |
HK1225968A1 (zh) | 用於治療hbv感染的組合療法 | |
PT3212233T (pt) | Terapia combinada para o tratamento de doenças | |
PT3286166T (pt) | Inibidores de replicação do vírus da imunodeficiência humana | |
EP3273955A4 (en) | TREATMENT OF RESPIRATORY DISEASES | |
HK1251009B (zh) | 用於治療癌症的治療組合物 | |
HK1258128A1 (zh) | 選擇病人接受組合療程 | |
HK1252343A1 (zh) | 用於治療病毒感染的組合物和方法 | |
HK1258994A1 (zh) | 用於疾病治療的方法 | |
HK1249865B (zh) | 疼痛的治療 | |
IL271965A (en) | Preparations containing a neoantigenic vaccine for the treatment of cancer | |
GB201516905D0 (en) | Treatment of Neurodegenerative diseases | |
HK1255221A1 (zh) | 使用卡多曲組合物進行治療的方法 | |
IL259710A (en) | Preparations and methods for the treatment of Davidson's disease (microvillus inclusion disease) and related diseases | |
SG11201605440TA (en) | Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome | |
HK1225995A1 (zh) | 用於治療或緩解高齡或晚期癌症患者的藥物組合物 | |
IL256919A (en) | Pharmaceutical compositions useful for the treatment of tissue damage | |
IL259381B (en) | Miravegron for the treatment of retinal diseases | |
IL252543B (en) | Compounds for the treatment of degenerative retinal tissues | |
IL247369A0 (en) | Compounds and methods for the treatment of bone diseases | |
GB201621398D0 (en) | Treatment of emt-associated disease | |
GB201501800D0 (en) | Treatment of medical conditions | |
GB201504413D0 (en) | Treatment of disease | |
AU2015901032A0 (en) | Treatment of respiratory diseases | |
IL236381A0 (en) | Pharmaceutical preparations for the treatment of cancer |